Navigation Links
NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
Date:11/9/2009

SAN DIEGO, Nov. 9 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2009 annual American College of Allergy, Asthma, and Immunology in Miami, Florida. The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance and Has Potent Anti-inflammatory Effects in Animal Models of Asthma".

DAS181 (Fludase®) is an investigational broad spectrum host-targeting drug candidate being studied in human clinical development for treatment and prevention of Influenza-Like Illness caused by any strains of influenza and parainfluenza. NexBio has recently announced the publication of two articles describing activity in non-clinical models of DAS181 for Pandemic Influenza A(H1N1) and for influenza resistant to Neuraminidase inhibitors (NAI), in a peer-reviewed journal.

The new data presented from studies in three animal models of asthma, done by NexBio's academic collaborators, demonstrate that DAS181 inhibits airway hyperreactivity, characteristic of asthma. DAS181 further decreases the number of inflammatory cells and mucous secreting cells in the respiratory tract. In the animal models, DAS181 is as effective as a bronchodilator or a steroid which are anti-asthma drugs on the market. People with asthma are prone to develop severe complications when they catch influenza. According to the Centers for Disease Control and Prevention (CDC), the majority of hospitalizations from the ongoing H1N1 Pandemic are in people with asthma.

The data were presented by Dr. Ronald Moss, NexBio's EVP of Clinical Development and Medical Affairs. "These data support the unique dual activities of DAS181. Because of its antiviral and anti-asthmatic properties, DAS181 may provide an alternative influenza treatment option for people with asthma and pre-existing respiratory diseases. This may be of a particular importance as there is increasing prevalence of drug resistance to Tamiflu®, and the other NAI on the market, Relenza®, is contraindicated for this population." said Dr. Moss.

ABOUT NEXBIO

NexBio, Inc. is a privately held clinical-stage biopharmaceutical company located in San Diego. NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase®), is an investigational drug that consists of an inhaled recombinant fusion protein. It inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under BAA Contract HHSN266200600015C and grant U01-AI070281. Viradin(TM), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP® is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP® is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

    * FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.

SOURCE NexBio, Inc.


'/>"/>
SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
Breaking Biology News(10 mins):